To me the Constellation sale is good for Zenith as it at least sets some kind of market value bar for a pre approval epigenetic cancer drug. If BDAZ is correct and Zenith has a more valuable pipeline this sale might at least give Don some added leverage for better valuations for financings if not an outright sale. Based on 135 million shares outstanding (I think that is about right) even a valuation of $1.75B USD would put Zenith at about $13/sh USD, far better than what we are doing financings at currently. Makes me think back, very optimistically :), to Dutchfellas better priced financing/sale rumours which he posted about.